CABOMETYX is indicated as monotherapy for aRCC- as 1L treatment of adult patients with intermediate or poor risk, per IMDC criteria. – in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. CABOMETYX, in combination with nivolumab, is indicated for the 1L treatment of aRCC in adults.

For full details please refer to the PI as approved by the IL MoH.